Sign in to continue:

Wednesday, February 25th, 2026

Westlake Chemical Partners LP Files Form 8-K Current Report with SEC – Company Information, Trading Symbol WLKP, and Exchange Details

Westlake Chemical Partners LP Announces Executive Retirement: CFO and Board Member M. Steven Bender to Step Down

Key Points:

  • Westlake Chemical Partners LP (NYSE: WLKP) has announced a significant leadership change.
  • On February 18, 2026, M. Steven Bender notified the General Partner, Westlake Chemical Partners GP LLC, of his intention to retire from his roles as Executive Vice President and Chief Financial Officer, as well as from the Board of Directors of the General Partner.
  • Bender’s retirement will be effective upon the appointment of his successor as Chief Financial Officer.
  • The company confirms that Mr. Bender’s decision to retire was not the result of any disagreement with the General Partner or the Partnership.

Details for Investors:

  • Leadership Change: The retirement of a senior executive, especially the CFO, is a material event that can impact investor confidence, company strategy, and financial reporting continuity.
  • No Disagreement: The filing explicitly states that Mr. Bender’s retirement is not due to any dispute or issue with the company, suggesting a planned transition rather than a sudden departure.
  • Succession Planning: The effective date of Bender’s retirement is tied to the appointment of his successor, indicating that WLKP is in the process of identifying or has identified a new CFO. Investors should monitor subsequent filings for information on the new appointment, as the choice of successor may impact the company’s strategic direction and financial stewardship.
  • Price Sensitivity: Leadership changes, especially in the finance function, are closely watched by shareholders and can be price sensitive. The market may react to the news depending on perceptions of the outgoing executive’s performance and the incoming successor’s credentials.

Additional Information:

  • Westlake Chemical Partners LP is incorporated in Delaware and headquartered at 2801 Post Oak Boulevard, Suite 600, Houston, TX 77056.
  • The company’s trading symbol is WLKP and its securities are listed on the New York Stock Exchange (NYSE).
  • There are no written communications, soliciting materials, or pre-commencement tender offers associated with this filing.
  • WLKP is not classified as an emerging growth company.

Implications for Shareholders:

  • Shareholders should pay close attention to the upcoming announcement of the new CFO. The appointment may affect investor sentiment concerning financial management and future company performance.
  • As the transition is stated to be amicable and planned, the stability of the management team is likely preserved, but the market may seek further details about the new leadership’s vision and experience.

Disclaimer

This article is based on information disclosed in the official Form 8-K filing by Westlake Chemical Partners LP dated February 18, 2026. It is intended for informational purposes only and does not constitute investment advice. Shareholders and prospective investors should conduct their own due diligence and consult with financial advisors before making any investment decisions. The information herein may be subject to change as further announcements are made by the company.

View Westlake Chemical Partners LP Historical chart here



Veea Inc. Secures $10.55 Million Loan from Pasadena Private Lending: Details of Loan Agreement, Covenants, and Guaranties

Veea Inc. SEC 8-K Filing: Detailed Investor Breakdown Veea Inc. Announces Entry into Material Definitive Agreement and Creation of Direct Financial Obligation Key Highlights from the SEC 8-K Filing Material Definitive Agreement: Veea Inc....

Invesco Mortgage Capital Inc. 2025 Annual Report: Business Overview, Risk Factors, Investment Strategies & Financial Insights

Invesco Mortgage Capital Inc. 2025 Annual Report – In-Depth Analysis for Investors Invesco Mortgage Capital Inc. 2025 Annual Report – Detailed Insights for Investors Key Highlights from the 2025 Annual 10-K Filing Form 10-K...

The Oncology Institute Appoints Kim Tzoumakas to Board of Directors, Expanding Value-Based Cancer Care

The Oncology Institute Appoints Kim Tzoumakas to Board of Directors The Oncology Institute Appoints Kim Tzoumakas to Board of Directors Key Points for Investors Appointment Announcement: The Oncology Institute, Inc. (NASDAQ: TOI), a leading...

   Ad